Blinatumomab

(Blincyto)

Blinatumomab

Drug updated on 11/10/2023

Dosage FormInjection (intravenous: 35 mcg)
Drug ClassCD19-directed CD3 T-cell engagers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adults and children with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
  • For the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL)

Product Monograph / Prescribing Information

Document TitleYearSource
Blincyto (blinatumomab) Prescribing Information.2023Amgen Inc., Thousand Oaks, California

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis.2023Frontiers in pharmacology
Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.2022Annals of Hematology
Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults.2022Expert Review of Hematology
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.2022Frontiers in pediatrics
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review)2021Journal of Clinical Medicine
Commonly reported adverse events associated with pediatric immunotherapy: a systematic review from the Children’s Oncology Group2021Journal of Pediatric Oncology Nursing
Evidence-based recommendations for nurse monitoring and management of immunotherapy-induced cytokine release syndrome: a systematic review from the Children’s Oncology Group.2021Journal of Pediatric Oncology Nursing
Efficacy of targeted immunotherapy as induction or salvage therapy in acute lymphoblastic leukemia: a systematic review and meta-analysis2021Technology in Cancer Research & Treatment
A systematic review of blinatumomab in the treatment of acute lymphoblastic leukemia: engaging an old problem with new solutions. 2021Annals of Pharmacotherapy
Final clinical guidance report: Blincyto (blinatumomab).2020CADTH
Commonly reported adverse events associated with pediatric immunotherapy: a systematic review from the children's oncology group.2020Journal of Pediatric Oncology Nursing
Final clinical guidance report: Blincyto (blinatumomab) for Philadelphia chromosome positive acute lymphoblastic Leukemia.2019CADTH
Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis.2019Hematology

Clinical Practice Guidelines